The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study
Open accessAbstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and imposes a substantial economic burden. Gaining a thorough understanding of the economic implications of COPD is an important prerequisite for sound, evidence-based policy making. We aimed to estimate the macroeconomic burden of COPD for each country and establish its distribution across world regions. METHODS: In this health-augmented macroeconomic modelling study we estimated the macroeconomic burden of COPD for 204 countries and territories over the period 2020-50. The model accounted for (1) the effect of COPD mortality and morbidity on labour supply, (2) age and sex specific differences in education and work experience among those affected by COPD, and (3) the impact of COPD treatment costs on physical capital accumulation. We obtained data from various public sources including the Global Burden of Disease Study 2019, the World Bank database, and the literature. The macroeconomic burden of COPD was assessed by comparing gross domestic product (GDP) between a scenario projecting disease prevalence based on current estimates and a counterfactual scenario with zero COPD prevalence from 2020 to 2050. FINDINGS: Our findings suggest that COPD will cost the world economy INT$4·326 trillion (uncertainty interval 3·327-5·516; at constant 2017 prices) in 2020-50. This economic effect is equivalent to a yearly tax of 0·111% (0·085-0·141) on global GDP. China and the USA face the largest economic burdens from COPD, accounting for INT$1·363 trillion (uncertainty interval 1·034-1·801) and INT$1·037 trillion (0·868-1·175), respectively. INTERPRETATION: The macroeconomic burden of COPD is large and unequally distributed across countries, world regions, and income levels. Our study stresses the urgent need to invest in global efforts to curb the health and economic burdens of COPD. Investments in effective interventions against COPD do not represent a burden but could instead provide substantial economic returns in the foreseeable future. FUNDING: Alexander von Humboldt Foundation, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Science, Chinese Academy of Engineering project, Chinese Academy of Medical Sciences and Peking Union Medical College project, and Horizon Europe. TRANSLATIONS: For the Chinese and German translations of the abstract see Supplementary Materials section.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Menezes, A. M., Sullivan, S. D., Lee, T. A., Weiss, K. B., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61377-4 · Cited by 2,366
The economic burden of physical inactivity: a global analysis of major non-communicable diseases
Ding, D., Lawson, K. D., Kolbe-Alexander, T. L., Finkelstein, E. A., Katzmarzyk, P. T., van Mechelen, W., & Pratt, M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30383-x · Cited by 2,201
(2012) · RePEc: Research Papers in Economics · Cited by 1,951
Singh, D., Agusti, A., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Criner, G. J., Frith, P., Halpin, D. M. G., Han, M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00164-2019 · Cited by 1,937
Measuring the global burden of disease
Murray, C. J. L., & Lopez, A. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1201534 · Cited by 1,818
Reitsma, M. B., Kendrick, P. J., Ababneh, E., Abbafati, C., Abbasi-Kangevari, M., Abdoli, A., Abedi, A., Abhilash, E. S., Abila, D. B., Aboyans, V., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01169-7 · Cited by 1,759
Self-citationWang, C., Xu, J., Yang, L., Xu, Y., Zhang, X., Bai, C., Kang, J., Ran, P., Shen, H., Wen, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30841-9 · Cited by 1,681
Self-citationUS Health Care Spending by Payer and Health Condition, 1996-2016
Dieleman, J. L., Cao, J., Chapin, A., Chen, C., Li, Z., Liu, A., Horst, C., Kaldjian, A., Matyasz, T., Scott, K. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.0734 · Cited by 1,313
Chen, S., Cao, Z., Prettner, K., Kuhn, M., Yang, J., Jiao, L., Wang, Z., Li, W., Geldsetzer, P., Bärnighausen, T., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7826 · Cited by 890
Self-citationThe Pathology of Chronic Obstructive Pulmonary Disease
Hogg, J. C., & Timens, W. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092145 · Cited by 845
Cited by
Chen, S., Cao, Z., Nandi, A., Counts, N., Jiao, L., Prettner, K., Kuhn, M., Seligman, B., Tortorice, D., Vigo, D., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00264-x · Cited by 294
Self-citationExploring explainable AI features in the vocal biomarkers of lung disease
Chen, Z., Liang, N., Li, H., Zhang, H., Li, H., Yan, L., Hu, Z., Chen, Y., Zhang, Y., Wang, Y., et al. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108844 · Cited by 26
Metadata
- Authors
- Chen, S., Kuhn, M., Prettner, K., Yu, F., Yang, T., Bärnighausen, T., Bloom, D. E., & Wang, C.
- Venue
- The Lancet Global Health
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 11
- Issue
- 8
- Pages
- e1183-e1193
- ISSN
- 2214-109X (ISSN-L)
- OpenAlex
- W4384925410
- Cited by
- 487
- References
- 25
- FWCI
- 77.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. https://app.cochat.ai/papers/10.1016/s2214-109x(23)00217-6
- The paper
- Chen, S., Kuhn, M., Prettner, K., Yu, F., Yang, T., Bärnighausen, T., Bloom, D. E., & Wang, C. (2023). The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(23)00217-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.